05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of cardiovascular, cardiopulmonary, pulmonary, and vascular diseases; Pharmaceutical preparations for the treatment of pulmonary hypertension
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of cardiovascular, cardiopulmonary, pulmonary, and vascular diseases; Pharmaceutical preparations for the treatment of pulmonary hypertension
3.
TREPROSTINIL DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
Provided are treprostinil derivatives with a reduced ability to form undesired impurities in a pharmaceutical formulation, such as a dry powder formulation, further containing a carboxyl group containing inactive ingredient, such as fumaryl dikctopiperazinc.
12 - Land, air and water vehicles; parts of land vehicles
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft (1) Research and development in the field of electrically powered aircraft
12 - Land, air and water vehicles; parts of land vehicles
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft (1) Research and development in the field of electrically powered aircraft
12 - Land, air and water vehicles; parts of land vehicles
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft (1) Research and development in the field of electrically powered aircraft
Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
A method of producing an oral osmotic pharmaceutical delivery system by using a statistical modeling. The method includes determining a desired average dissolution profile for the active pharmaceutical ingredient; and controlling tablet strength, acetyl content of the cellulose acetate and weight gain of the semi-permeable membrane of the tablet to produce a pharmaceutical batch of tablets having the desired dissolution profile.
12 - Land, air and water vehicles; parts of land vehicles
42 - Scientific, technological and industrial services, research and design
Goods & Services
Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft Research and development in the field of electrically powered aircraft
12 - Land, air and water vehicles; parts of land vehicles
42 - Scientific, technological and industrial services, research and design
Goods & Services
Aircraft; Electrically powered aircraft; Vertical take-off and landing (VTOL) aircraft Research and development of technology in the field of electrically powered aircraft
11.
A METHOD OF PRODUCING AN ORAL OSMOTIC PHARMACEUTICAL DELIVERY SYSTEM AND A PHARMACEUTICAL BATCH PRODUCED USING THE SAME
A method of producing an oral osmotic pharmaceutical delivery system by using a statistical modeling. The method includes determining a desired average dissolution profile for the active pharmaceutical ingredient; and controlling tablet strength, acetyl content of the cellulose acetate and weight gain of the semi-permeable membrane of the tablet to produce a pharmaceutical batch of tablets having the desired dissolution profile.
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
13.
A HIGH RESOLUTION PRINTING SYSTEM AND A METHOD OF ALIGNING PIXELATED TILES
A three-dimensional printing apparatus is configured to manufacture a 3D article in a layer-layer manner. The 3D printing apparatus includes a projector configured to selectively irradiate a photosensitive apparatus along a horizontal build plane defined along X and Y axes. The projector is coupled to a lateral movement mechanism configured to laterally scan the projector along X' and Y' axial movement coordinates. The X' and Y' axial movement coordinates are not exactly aligned with the X and Y axes respectively. For individual layers of the 3D article, the projector is configured to irradiate a sequence of adjacent pixelated tiles within the build plane. Before irradiating the sequence of tiles, the projector is configured to operate a camera and to align leading (46, 46-1) and trailing edges (48, 48-2) of the tiles along each of X' and Y'.
B29C 64/135 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask the energy source being concentrated, e.g. scanning lasers or focused light sources
B29C 64/236 - Driving means for motion in a direction within the plane of a layer
A three-dimensional (3D) printing apparatus is configured to manufacture a 3D article in a layer-layer manner. The 3D printing apparatus includes a projector configured to selectively irradiate a photosensitive apparatus along a horizontal build plane defined along X and Y axes. The projector is coupled to a lateral movement mechanism configured to laterally scan the projector along X′ and Y′ axial movement coordinates. The X′ and Y′ axial movement coordinates are not exactly aligned with the X and Y axes respectively. For individual layers of the 3D article, the projector is configured to irradiate a sequence of adjacent pixelated tiles within the build plane. Before irradiating the sequence of tiles, the projector is configured to operate a camera and to align leading and trailing edges of the tiles along each of X′ and Y′.
B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
B29C 64/129 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask
B29C 64/232 - Driving means for motion along the axis orthogonal to the plane of a layer
B29C 64/255 - Enclosures for the building material, e.g. powder containers
e.ge.g., culture media) for culturing iPS cells, such as iPS-endothelial cells (iPS-ECs). The present disclosure also provides iPS-EC cultures comprising iPS-ECs and a culture medium.
The present disclosure relates generally to, among other things, methods and compositions (e.g., culture media) for culturing iPS cells, such as iPS-endothelial cells (IPS-ECs). The present disclosure also provides iPS-EC cultures comprising iPS-ECs and a culture medium.
The present disclosure relates to CCL20 promoters derived from the regulatory region of the CCL20 gene that stimulate gene expression in response to inflammation. These CCL20 promoters, which can be stimulated by an endogenous or exogenous cytokine, can be used to control the timing of the expression of a heterologous gene. The present disclosure also relates to expression cassettes or vectors comprising the CCL20 promoters of the present disclosure operably linked to a nucleic acid sequence encoding, e.g., a polypeptide of interest, as well as delivery systems (e.g., viral particles, lipid vesicles, or nanoparticles) or cells comprising such expression cassettes or vectors. The present disclosure also relates to the use of the promoters, expression cassettes, vectors, delivery systems, or cells in the treatment of diseases related to inflammation, or for recombinant gene expression.
Provided are methods, polynucleotides and compositions for the generation of engineered Treg cells. The methods, polynucleotides and compositions enable the reprogramming of hematopoietic cells into Treg cells by constitutive or regulated expression of FOXP3 in engineered cells such that the engineered Treg cells can suppress the activation and proliferation of responder T cells.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present disclosure provides novel serology methods for detecting viremic or latent zoonotic viral infections, such as porcine cytomegalovirus (PCMV) or Porcine lymphotropic herpesvirus (PLHV) infections, in a subject at any stage of development. More specifically, the present disclosure provides an automated multiplexed immunoassay for the rapid and simultaneous detection of one or more anti-PCMV antibodies or anti-PLHV antibodies in biological fluids of a subject suspected of being infected with PCMV or PLHV.
Modular synthetic receptors are provided. The synthetic receptors may include an extracellular domain capable of binding to one or more ligand molecules and may be released from the synthetic receptor after binding, a transmembrane domain derived from the Notch receptor, and an intracellular domain which may have one or more functional activities when released from the synthetic receptor. A method of use for the synthetic receptors is also provided, wherein upon binding of the extracellular domain to a specific ligand, the synthetic receptor undergoes proteolytic cleavage to release either or both the extracellular and intracellular domains. The extracellular binding domain, if released, may continue to bind to its cognate ligand and may carry one or more additional functional activities and the intracellular domain, if released, may stimulate or inhibit one or more intracellular activities.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
22.
SEROLOGY ASSAY FOR THE DETECTION OF PORCINE VIRUSES
The present disclosure provides novel serology methods for detecting viremic or latent zoonotic viral infections, such as porcine cytomegalovirus (PCMV) or Porcine lymphotropic herpesvirus (PLHV) infections, in a subject at any stage of development. More specifically, the present disclosure provides an automated multiplexed immunoassay for the rapid and simultaneous detection of one or more anti-PCMV antibodies or anti-PLHV antibodies in biological fluids of a subject suspected of being infected with PCMV or PLHV.
Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure:
Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure:
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 31/558 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
24.
BICISTRONIC CONSTRUCTS FOR ALLOGENEIC GENE THERAPY
The present disclosure relates to bicistronic polypeptide constructs for use in allogeneic gene therapy, for example, CAR-T cell therapy. The bicistronic constructs comprise first polynucleotide encoding a therapeutic molecule (e.g., a CAR-T or an antibody) and a second polynucleotide encoding an Immune Surveillance Masking Molecule (ISMM). The ISMM comprises a human leukocyte antigen-E genetically fused to a non-functional version, e.g., a fragment, of the protein knock-out by the insertion of the bicistronic construct, e.g., beta-2 microglobulin or B2M. Also provided are vectors comprising the bicistronic constructs, cells (e.g., CAR-T cells), and methods of use. Also provided are kits and articles of manufacture. The present disclosure also provides four novel insertion sites that can be used to insert an expression construct in the B2M gene.
Provided are methods, polynucleotides and compositions for the generation of engineered Treg cells. The methods, polynucleotides and compositions enable the reprogramming of hematopoietic cells into Treg cells by constitutive or regulated expression of FOXP3 in engineered cells such that the engineered Treg cells can suppress the activation and proliferation of responder T cells.
A method of modifying a surface of a three-dimensional (3D) article includes immersing at least one part of the 3D article in a buffered solution of functionalized peptides, allowing reaction between the functionalized peptides and reactive groups on the surface of the 3D article; and washing the at least one part of the 3D article to remove unreacted functionalized peptides. The surface-modified 3D article includes a plurality of peptides covalently bonded to the surface of the 3D article via a cysteine bridge. The surface- modified 3D article can be used as a scaffold for the formation of biological tissue or bodily implants.
An automated bioreactor system for decellularizing an organ includes a main chamber for containing the organ. The system further includes a reagent chamber containing a liquid phase reagent. A reagent conduit delivers the liquid phase reagent to the main chamber, and a perfusion conduit delivers the reagent from the reagent outlet in the main chamber into the organ. A perfusion pump drives the flow of the reagent. A perfusion pressure sensor detects a pressure of the flowing reagent. A control system controls the perfusion pump to drive the flow of the reagent based on a received input representative of a desired pressure and a received input of the detected pressure. The control system may automatically perform all of the steps of a decellularization protocol based on sensor input. An automated waste decontamination system may also be provided.
A method of modifying a surface of a three-dimensional (3D) article includes immersing at least one part of the 3D article in a buffered solution of functionalized peptides, allowing reaction between the functionalized peptides and reactive groups on the surface of the 3D article; and washing the at least one part of the 3D article to remove unreacted functionalized peptides. The surface-modified 3D article includes a plurality of peptides covalently bonded to the surface of the 3D article via a cysteine bridge. The surface-modified 3D article can be used as a scaffold for the formation of biological tissue or bodily implants.
The present disclosure relates to CCL20 promoters derived from the regulatory region of the CCL20 gene that stimulate gene expression in response to inflammation. These CCL20 promoters, which can be stimulated by an endogenous or exogenous cytokine, can be used to control the timing of the expression of a heterologous gene. The present disclosure also relates to expression cassettes or vectors comprising the CCL20 promoters of the present disclosure operably linked to a nucleic acid sequence encoding, e.g., a polypeptide of interest, as well as delivery systems (e.g., viral particles, lipid vesicles, or nanoparticles) or cells comprising such expression cassettes or vectors. The present disclosure also relates to the use of the promoters, expression cassettes, vectors, delivery systems, or cells in the treatment of diseases related to inflammation, or for recombinant gene expression.
The present disclosure relates to bicistronic polypeptide constructs for use in allogeneic gene therapy, for example, CAR-T cell therapy. The bicistronic constructs comprise first polynucleotide encoding a therapeutic molecule (e.g., a CAR-T or an antibody) and a second polynucleotide encoding an Immune Surveillance Masking Molecule (ISMM). The ISMM comprises a human leukocyte antigen-E genetically fused to a non-functional version, e.g., a fragment, of the protein knock-out by the insertion of the bicistronic construct, e.g., beta-2 microglobulin or B2M. Also provided are vectors comprising the bicistronic constructs, cells (e.g., CAR-T cells), and methods of use. Also provided are kits and articles of manufacture. The present disclosure also provides four novel insertion sites that can be used to insert an expression construct in the B2M gene.
Provided are novel treprostinil derivatives, including treprostinil prodrugs and treprostinil analogs, as well as methods of making and using these compounds.
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
C07C 69/712 - Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
Provided herein are methods which alter the mechanical and biological properties of polymeric materials. Also provided are compositions comprising the polymeric materials having said properties.
B29C 64/188 - Processes of additive manufacturing involving additional operations performed on the added layers, e.g. smoothing, grinding or thickness control
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
Goods & Services
Patient support services on behalf of pharmaceutical manufacturers for the benefit of patients of pharmaceutical manufacturers including enrolling patients of pharmaceutical manufacturers in support programs that enables the patients to view, track and manage the support program wherein the patient support program provides pharmaceutical product and medication education, medication adherence support, visibility into medication delivery and case status, clinical support services, access to financial assistance programs, payer coverage status updates, patient engagement services and reminders and notifications Providing information to patients and caregivers on available financial support for pharmaceutical treatments Educational services, namely, online and telephone coaching for patients and caregivers about disease management and treatment information to improve understanding by patients and caregivers about pharmaceutical treatments and administration
Provided are novel methods of treating pulmonary hypertension comprising monitoring mean pulmonary arterial pressure in a subject, administering a first therapeutically effective amount of a pulmonary vasodilator when mean pulmonary pressure exceeds a threshold value in the subject, and administering an increasing dose of the pulmonary vasodilator until mean pulmonary arterial pressure is reduced.
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
Provided are novel treprostinil derivatives, including treprostinil prodrugs and treprostinil analogs, as well as methods of making and using these compounds.
C07C 69/63 - Halogen-containing esters of saturated acids
C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
Provided are novel methods of treating pulmonary hypertension comprising monitoring mean pulmonary arterial pressure in a subject, administering a first therapeutically effective amount of a pulmonary vasodilator when mean pulmonary pressure exceeds a threshold value in the subject, and administering an increasing dose of the pulmonary vasodilator until mean pulmonary arterial pressure is reduced.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
The present disclosure relates to methods of differentiating pluripotent stem cells into endothelial cells. The present disclosure also relates to endothelial cells made by such methods, organoids containing such endothelial cells, and methods of use thereof. The present disclosure also relates to differentiation media for use in the same.
A method of manufacturing a three-dimensional (3D) article includes operating a print engine to fabricate a composite structure including the 3D article coupled to a support structure, removing the composite structure from the fluid tank, and peeling the inside surface of the sheath away from the outer surface of the article, peeling progressively breaks the plurality of strands. The support structure includes a conformal sheath having an inside surface that follows the outer surface of the 3D article with a gap between the inside surface of the sheath and the outer surface of the article, and a plurality of strands that span the gap and individually have opposed ends that are coupled to the inside surface of the sheath and the outer surface of the article to maintain the gap, the gap filled with the photocurable liquid ink.
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
B29C 64/40 - Structures for supporting 3D objects during manufacture and intended to be sacrificed after completion thereof
The present disclosure provides for treating pulmonary hypertension by administering to a subject suffering from pulmonary hypertension a therapeutically effective amount of a non-oral therapeutic agent for treating pulmonary hypertension followed by an orally administered form of a therapeutic agent for treating pulmonary hypertension, wherein the amount of non-oral therapeutic agent is sufficient to allow for an increased amount of the orally administered therapeutic agent to thereafter be administered compared to a subject who is not previously treated with the non-oral therapeutic agent.
An advanced manufactured interpenetrating polymer network (AM-IPN) comprising: a primary polymer network; a secondary polymer network, wherein the secondary polymer network is bonded to the primary polymer network via one or more crosslinks, wherein one or more of the primary polymer network, the secondary polymer network and the one or more crosslinks are printed using a synthetic bioink is disclosed. Methods of making and using are also disclosed.
C09D 4/06 - Coating compositions, e.g. paints, varnishes or lacquers, based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond in combination with a macromolecular compound other than an unsaturated polymer of groups
B33Y 70/00 - Materials specially adapted for additive manufacturing
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
A method of manufacturing a three-dimensional (3D) article includes operating a print engine to fabricate a composite structure including the 3D article coupled to a support structure, removing the composite structure from the fluid tank, and peeling the inside surface of the sheath away from the outer surface of the article, peeling progressively breaks the plurality of strands. The support structure includes a conformal sheath having an inside surface that follows the outer surface of the 3D article with a gap between the inside surface of the sheath and the outer surface of the article, and a plurality of strands that span the gap and individually have opposed ends that are coupled to the inside surface of the sheath and the outer surface of the article to maintain the gap, the gap filled with the photocurable liquid ink.
B29C 64/40 - Structures for supporting 3D objects during manufacture and intended to be sacrificed after completion thereof
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
The present disclosure provides for treating pulmonary hypertension by administering to a subject suffering from pulmonary hypertension a therapeutically effective amount of a non-oral therapeutic agent for treating pulmonary hypertension followed by an orally administered form of a therapeutic agent for treating pulmonary hypertension, wherein the amount of non-oral therapeutic agent is sufficient to allow for an increased amount of the orally administered therapeutic agent to thereafter be administered compared to a subject who is not previously treated with the non-oral therapeutic agent.
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/6615 - Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
48.
TREATMENT OF PULMONARY ARTERIAL HYPERTENSION WITH PROSTACYCLIN-TREATED ENDOTHELIAL PROGENITOR CELLS
The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61K 35/02 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
50.
TREATMENT OF VASCULOPATHY WITH PROSTACYCLIN AND MESENCHYMAL STEM CELLS
Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present disclosure relates to methods of differentiating pluripotent stem cells into stromal cells or pericytes. The present disclosure also relates to stromal cells or pericytes made by such methods, organoids containing such stromal cells or pericytes, and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
The present disclosure relates to methods of differentiating pluripotent stem cells or lung progenitor cells into epithelial or basal cells. The present disclosure also relates to epithelial or basal cells made by such methods, organoids containing such epithelial or basal cells, and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
The present disclosure relates to methods of differentiating pluripotent stem cells or lung progenitor cells into alveolar type 2 (AT2) cells. The present disclosure also relates to AT2 cells made by such methods, organoids containing such AT2 cells and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
An advanced manufactured interpenetrating polymer network (AM-IPN) comprising: a primary polymer network; a secondary polymer network, wherein the secondary polymer network is bonded to the primary polymer network via one or more crosslinks, wherein one or more of the primary polymer network, the secondary polymer network and the one or more crosslinks are printed using a synthetic bioink is disclosed. Methods of making and using are also disclosed.
An advanced manufactured transwell (AM-transwell), the AM-transwell comprises: a lower chamber; an upper chamber; a membrane disposed between the lower chamber and the upper chamber; and one or more legs. The one or more legs form at least a portion of the lower chamber. One or more of the lower chambers, the upper chamber, the membrane and the one or more legs is printed using a synthetic bioink. Methods for making and using the AM-transwell are also disclosed.
An advanced manufactured transwell (AM-transwell), the AM-transwell comprises: a lower chamber; an upper chamber; a membrane disposed between the lower chamber and the upper chamber; and one or more legs. The one or more legs form at least a portion of the lower chamber. One or more of the lower chambers, the upper chamber, the membrane and the one or more legs is printed using a synthetic bioink. Methods for making and using the AM-transwell are also disclosed.
The present disclosure relates to methods of differentiating pluripotent stem cells into endothelial cells. The present disclosure also relates to endothelial cells made by such methods, organoids containing such endothelial cells, and methods of use thereof. The present disclosure also relates to differentiation media for use in the same.
The present disclosure relates to methods of differentiating pluripotent stem cells or lung progenitor cells into epithelial or basal cells. The present disclosure also relates to epithelial or basal cells made by such methods, organoids containing such epithelial or basal cells, and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
The present disclosure relates to methods of differentiating pluripotent stem cells or lung progenitor cells into alveolar type 2 (AT2) cells. The present disclosure also relates to AT2 cells made by such methods, organoids containing such AT2 cells and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
The present disclosure relates to methods of differentiating pluripotent stem cells into stromal cells or pericytes. The present disclosure also relates to stromal cells or pericytes made by such methods, organoids containing such stromal cells or pericytes, and methods of using the same. The present disclosure also relates to differentiation media for use in the same.
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound, such as but not limited to pulmonary hypertension (PH) diseases.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
C07D 295/195 - Radicals derived from nitrogen analogues of carboxylic acids
64.
Crystalline prostacyclin (IP) receptor agonist and uses thereof
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
Nebulizers and inhalers for administering medication in the form of a mist inhaled into the lungs, for treatment of pulmonary hypertension and heart and lung diseases
42 - Scientific, technological and industrial services, research and design
Goods & Services
Software as a Service (SAAS) services featuring software for monitoring the delivery of and implant procedure for organ transplants, for monitoring and reporting statistics on the health of the organ, its viability for transport and transplant, its current location and times for various events involved in the organ delivery and transplant process, and enabling instant user access for, and communication among, all parties involved in the organ delivery and transplant process, including doctors, hospital and transport staff, and medical and medical research personnel
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Human organs, organ tissue, and organ parts for transplantation; medical implant devices, namely, implants consisting primarily of biological materials, and implants consisting of a combination of biological and artificial materials, all of which are derived, at least in part, from human organ tissue for use in transplantation Medical and scientific research in the field of preservation, modification, and engineering of human organs Specialized medical services, namely, rehabilitation of human organs, organ tissue, and organ parts for transplantation; health care services, namely, services to perfuse human organs, organ tissue, and organ parts after recovery from an organ donor and before transplantation into a recipient
73.
PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN®
This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
C07C 51/08 - Preparation of carboxylic acids or their salts, halides, or anhydrides from nitriles
C07C 51/41 - Preparation of salts of carboxylic acids by conversion of the acids or their salts into salts with the same carboxylic acid part
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
C07C 59/72 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
C07C 405/00 - Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins
C07C 253/00 - Preparation of carboxylic acid nitriles
refrigerated transport containers for use in the cold storage of organs for transplant nonmetal and non-paper containers for storage and transport of organs for transplant
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound, such as but not limited to pulmonary hypertension (PH) diseases.
A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound, such as but not limited to pulmonary hypertension (PH) diseases.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
C07C 269/08 - SeparationPurificationStabilisationUse of additives
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
79.
CRYSTALLINE PROSTACYCLIN (IP) RECEPTOR AGONIST AND USES THEREOF
Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
An apparatus (100) for printing a 3D model, comprising: a vat (106) configured to store a photocurable ink, wherein a bottom of the vat comprises an oxygen permeable membrane (105), and a printing platform (116) comprising: a base (118), and a mesh at a first side of the base, wherein an adhesion strength between a photocurable ink to the mesh is greater than an adhesion strength of the photocurable ink to the oxygen permeable membrane, wherein the platform is configured to be displaced from the oxygen permeable membrane to form a 3D model from the photocurable ink.
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
A platform form an apparatus for printing a 3D model comprises a base and a print layer. The base has a first side where the first side of the base has a first surface roughness thereon. The print layer is coupled first side of the base and includes a surface. The surface of the print layer is distal from the base and has a second surface roughness which is greater than the first surface roughness so as to promote adhesion of the 3D model being printed on the platform.
The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.
An apparatus (100) for printing a 3D model, comprising: a vat (106) configured to store a photocurable ink, wherein a bottom of the vat comprises an oxygen permeable membrane (105), and a printing platform (116) comprising: a base (118), and a mesh at a first side of the base, wherein an adhesion strength between a photocurable ink to the mesh is greater than an adhesion strength of the photocurable ink to the oxygen permeable membrane, wherein the platform is configured to be displaced from the oxygen permeable membrane to form a 3D model from the photocurable ink.
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
87.
METHODS AND COMPOSITIONS FOR IMPROVING ENDOTHELIAL CELL BARRIER
Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine- 1 -phosphate (SIP) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.
A printable composition for the manufacture of cell-receiving scaffolds comprising about 0.3 wt % to about 3.0 wt % of one or more collagens; about 5.0 wt % to about 40.0 wt % of one or more monomers; about 0.5 wt % to about 2.0 wt % of a photo initiator; and 0 wt % to about 75 wt % of a vehicle comprising a protic solvent, by weight of the printable composition; wherein the printable composition has a resolution of about 100 microns or less when printed, a photo speed (Dp/Ec) of about 0.1-5 mm (Dp) and about 10-100 mJ/cm2 (Ec) when printed, and a green strength of at least about 5 kPa after drying. The present technology further includes methods of manufacturing a three-dimensional cell-receiving scaffold using the printable composition.
B33Y 70/00 - Materials specially adapted for additive manufacturing
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
89.
METHODS AND COMPOSITIONS FOR IMPROVING ENDOTHELIAL CELL BARRIER
Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine- 1 -phosphate (SIP) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.
Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine-1-phosphate (S1P) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.
C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
92.
TRIPLY PERIODIC MINIMAL SURFACES FOR 3D PRINTED ORGANS AND TISSUES
An apparatus can include a triply periodic minimal surface. The apparatus can include a 3D scaffold formed from the triply periodic minimal surface. The apparatus can include one or more channels formed by the 3D scaffold. A method of forming a gas exchange unit can include printing a 3D scaffold formed from a triply periodic minimal surface. The 3D scaffold can include a vascular network configured to conduct a fluid. The 3D scaffold can include one or more channels configured to hold a gas. The vascular network can be embedded inside walls of the 3D scaffold. The one or more channels can be positioned between the walls of the 3D scaffold.
An apparatus can include a triply periodic minimal surface. The apparatus can include a 3D scaffold formed from the triply periodic minimal surface. The apparatus can include one or more channels formed by the 3D scaffold. A method of forming a gas exchange unit can include printing a 3D scaffold formed from a triply periodic minimal surface. The 3D scaffold can include a vascular network configured to conduct a fluid. The 3D scaffold can include one or more channels configured to hold a gas. The vascular network can be embedded inside walls of the 3D scaffold. The one or more channels can be positioned between the walls of the 3D scaffold.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
B33Y 70/00 - Materials specially adapted for additive manufacturing
An apparatus can include a triply periodic minimal surface. The apparatus can include a 3D scaffold formed from the triply periodic minimal surface. The apparatus can include one or more channels formed by the 3D scaffold. A method of forming a gas exchange unit can include printing a 3D scaffold formed from a triply periodic minimal surface. The 3D scaffold can include a vascular network configured to conduct a fluid. The 3D scaffold can include one or more channels configured to hold a gas. The vascular network can be embedded inside walls of the 3D scaffold. The one or more channels can be positioned between the walls of the 3D scaffold.
A method of printing a hydrogel scaffold is provided which includes providing a container containing an ink and a liquid that is immiscible with the ink; applying light from a light source to the ink to form a portion of the hydrogel scaffold, and applying light from a light source one or more additional times to produce one or more additional portions of the hydrogel scaffold.
B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
B29C 64/129 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask
96.
ENHANCEMENT OF MSC IMMUNOMODULATORY PROPERTIES BY TREPROSTINIL
Provided are methods for treating or preventing vasculopathy comprising administering to a subject in need thereof, ac composition comprising a mesenchymal stem cell (MSC), or a part of a culture medium that has been in contact with the MSC and comprises one or more components of the MSC, or an exosome derived from the MSC. Pharmaceutical compositions suitable for such treatment is also provided.
A method of printing a hydrogel scaffold is provided which includes providing a container containing an ink and a liquid that is immiscible with the ink; applying light from a light source to the ink to form a portion of the hydrogel scaffold, and applying light from a light source one or more additional times to produce one or more additional portions of the hydrogel scaffold.
B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
B29C 64/129 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask
98.
Two-phase 3D printing methods of forming biocompatible structures with immiscible liquids
A method of printing a hydrogel scaffold is provided which includes providing a container containing an ink and a liquid that is immiscible with the ink; applying light from a light source to the ink to form a portion of the hydrogel scaffold; and applying light from a light source one or more additional times to produce one or more additional portions of the hydrogel scaffold.
B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
B29K 105/00 - Condition, form or state of moulded material
The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.
Systems and methods are provided for evaluating a tissue that utilize a resistance to represent pressure of a fluid or gas passing through the tissue and a capacitance to represent compliance of the tissue.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
A61B 5/021 - Measuring pressure in heart or blood vessels
